Preliminary experience with drug-coated balloon angioplasty in primary percutaneous coronary intervention
Autor: | Than Htike Aung, Fahim Haider Jafary, Kwok Kong Loh, Hee Hwa Ho, Yau Wei Ooi, Dasdo Antonius Sinaga, Nwe Tun Yin, Julian Tan, Paul Jau Lueng Ong |
---|---|
Rok vydání: | 2015 |
Předmět: |
medicine.medical_specialty
Ejection fraction business.industry medicine.medical_treatment Percutaneous coronary intervention Thrombolysis medicine.disease Balloon Surgery Angioplasty Conventional PCI medicine Therapeutics Advances Myocardial infarction cardiovascular diseases Cardiology and Cardiovascular Medicine business TIMI |
Zdroj: | World journal of cardiology. 7(6) |
ISSN: | 1949-8462 |
Popis: | We evaluated the clinical feasibility of using drug-coated balloon (DCB) angioplasty in patients undergoing primary percutaneous coronary intervention (PPCI). Between January 2010 to September 2014, 89 ST-elevation myocardial infarction patients (83% male, mean age 59 ± 14 years) with a total of 89 coronary lesions were treated with DCB during PPCI. Clinical outcomes are reported at 30 d follow-up. Left anterior descending artery was the most common target vessel for PCI (37%). Twenty-eight percent of the patients had underlying diabetes mellitus. Mean left ventricular ejection fraction was 44% ± 11%. DCB-only PCI was the predominant approach (96%) with the remaining 4% of patients receiving bail-out stenting. Thrombolysis in Myocardial Infarction (TIMI) 3 flow was successfully restored in 98% of patients. An average of 1.2 ± 0.5 DCB were used per patient, with mean DCB diameter of 2.6 ± 0.5 mm and average length of 23.2 ± 10.2 mm. At 30-d follow-up, there were 4 deaths (4.5%). No patients experienced abrupt closure of the infarct-related artery and there was no reported target-lesion failure. Our preliminary experience showed that DCB angioplasty in PPCI was feasible and associated with a high rate of TIMI 3 flow and low 30-d ischaemic event. |
Databáze: | OpenAIRE |
Externí odkaz: |